Drug cGMP Basics: 21 CFR Parts 210 and 211 for Foreign Manufacturers

What Is cGMP and Why Does It Matter?

Current Good Manufacturing Practice (cGMP) regulations establish the minimum requirements for the methods, facilities, and controls used in manufacturing, processing, packing, and holding drug products. The "c" in cGMP stands for "current," meaning manufacturers must keep up with the latest technology and scientific understanding — static compliance with outdated practices is not sufficient.

The legal authority for cGMP comes from Section 501(a)(2)(B) of the FD&C Act, which deems a drug product "adulterated" if the methods, facilities, or controls used in its manufacture do not conform to cGMP. This means a drug can be considered adulterated even if final product testing shows it meets specifications — if the manufacturing process was not properly controlled, the product is legally adulterated.

For foreign manufacturers, cGMP compliance is not optional simply because the facility is outside U.S. jurisdiction. Under 21 CFR §211.1, the regulations apply to "the preparation of any drug product for administration to humans or animals." FDA conducts inspections of foreign drug manufacturing facilities, and non-compliance can result in:

• Import Alerts — allowing DWPE (detention without physical examination) of all products from the facility
• Warning Letters — requiring corrective action within 15 working days
• Refusal of new drug applications (NDA/ANDA) citing the facility
• Withdrawal of existing approvals if cGMP deficiencies are severe enough

Part 210: General Provisions

21 CFR Part 210 contains the general cGMP provisions and definitions that apply to all drug manufacturing. While Part 210 is short (only a few sections), it establishes critical foundational concepts:

• §210.1 — Status of current good manufacturing practice regulations: Establishes that Parts 210 and 211 contain the minimum cGMP for drug products. Also states that the regulations in these parts shall be considered as supplementing, not superseding, all other applicable regulations.
• §210.2 — Applicability: Parts 210 and 211 apply to all drug products for human use. For medicated animal feeds and medicated premixes, separate regulations (Parts 225 and 226) apply.
• §210.3 — Definitions: Defines key terms used throughout Part 211, including "act," "batch," "component," "drug product," "fiber," "lot," "lot number," "quality control unit," and many others.

The definitions in §210.3 are particularly important because they establish precise regulatory meanings. For example, "component" is defined as any ingredient intended for use in the manufacture of a drug product, including those that may not appear in the finished product. "Quality control unit" is defined as an organizational element having the authority and responsibility to approve or reject components, packaging, and finished products.

Part 211: Detailed cGMP Requirements

21 CFR Part 211 is the detailed regulation that specifies how drugs must be manufactured. It is organized into 11 subparts:

Subpart B — Organization and Personnel (§211.22–§211.34)

Requires a quality control unit with the authority to approve or reject all procedures and specifications affecting identity, strength, quality, and purity. Personnel must have adequate education, training, and experience. The facility must have enough qualified personnel. cGMP training must be conducted regularly, and hygiene and health requirements (including gowning procedures) must be established and followed.

Subpart C — Buildings and Facilities (§211.42–§211.58)

Facilities must be of suitable size, construction, and location. Separate or defined areas must be provided for operations to prevent contamination and mix-ups. Adequate lighting, ventilation, plumbing, and sanitation are required. Specific requirements address aseptic processing areas, which must meet environmental controls for air filtration, temperature, humidity, and pressure differentials.

Subpart D — Equipment (§211.63–§211.72)

Equipment must be of appropriate design, adequate size, and suitably located for intended use, cleaning, and maintenance. Equipment surfaces that contact components or drug products must be non-reactive, non-additive, and non-absorptive. Equipment cleaning and maintenance must be documented, and calibration of instruments must occur at suitable intervals.

Production, Laboratory, and Packaging Controls

Subpart F — Production and Process Controls (§211.100–§211.115)

Written procedures are required for production and process control, designed to ensure that drug products have the identity, strength, quality, and purity they purport or represent to have. Key requirements include:

• Master production and control records for each drug product
• Batch production records executed for each batch, documenting every step of manufacturing with dates, times, quantities, and operator signatures
• Appropriate in-process controls such as checking weights, disintegration times, mixing adequacy, and other parameters
• Yield calculations and investigation of significant discrepancies

Subpart I — Laboratory Controls (§211.160–§211.176)

Laboratory controls must include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures. Key requirements:

• Testing and release of each batch of drug product before distribution
• Identity testing of each component used in manufacturing
• Stability testing programs to determine appropriate expiration dates
• Reserve samples — adequate samples of each batch retained for at least one year after expiration date
• Out-of-specification (OOS) investigation procedures
• Reference standards — use of USP/NF reference standards where applicable

Subpart G — Packaging and Labeling Controls (§211.122–§211.137)

Packaging and labeling operations must be controlled to prevent mix-ups. Labeling materials must be stored and issued in a manner that prevents confusion between different products. Each container must bear an expiration date determined by appropriate stability testing. Tamper- evident packaging is required for OTC drug products.

Records, Returns, and Complaints

Subpart J — Records and Reports (§211.180–§211.198)

cGMP requires comprehensive record-keeping across all aspects of drug manufacturing. Records must be retained for at least one year after the expiration date of the batch (or two years after distribution for OTC products without expiration dates). Required records include:

• Equipment cleaning and use logs
• Component, container, and closure records
• Master production and control records
• Batch production and control records
• Laboratory records
• Distribution records (sufficient to permit recall if necessary)
• Complaint files — all written and oral complaints regarding a drug product must be recorded and investigated

Subpart K — Returned and Salvaged Drug Products (§211.204–§211.208)

Returned drug products must be identified, held, and evaluated before any decision is made about reprocessing or destruction. Drug products subjected to improper conditions (temperature excursions, water damage, etc.) cannot be salvaged unless they meet all specifications after reprocessing and testing.

Special Considerations for Foreign Manufacturers

Foreign drug manufacturers face additional considerations when demonstrating cGMP compliance:

• FDA foreign inspections — FDA inspects foreign drug facilities on a risk-based schedule. As of 2026, FDA conducts approximately 1,000 foreign drug inspections per year. Facilities must be prepared for unannounced or short-notice inspections.
• Pre-Approval Inspections (PAI) — if you are filing an NDA or ANDA, FDA will inspect your facility before approving the application. PAIs are thorough and focus on the specific product(s) in the application.
• Language considerations — while FDA does not require that all records be in English, investigators may request translations of key documents during inspections. Having critical SOPs and batch records available in English (or providing translators) facilitates smoother inspections.
• U.S. Agent requirement — foreign drug establishments must designate a U.S. Agent who serves as the FDA point of contact. The U.S. Agent may receive inspection notices and must forward them promptly.
• Import Alerts — cGMP violations at foreign facilities frequently result in Import Alerts, which allow U.S. Customs and FDA to detain shipments without physical examination. Removal from an Import Alert requires demonstrating corrective action and often a reinspection.
• Mutual Recognition Agreements (MRA) — FDA has MRAs with several regulatory authorities (EU, UK, Australia, Canada, others) that allow recognition of foreign inspections. If your facility has been inspected by an MRA partner authority, it may affect FDA's inspection scheduling.

Maintaining robust cGMP systems is not just a regulatory requirement — it is the foundation of product quality and patient safety. For foreign manufacturers seeking to enter or maintain access to the U.S. market, cGMP compliance is non-negotiable.

Assurentry helps foreign drug manufacturers with U.S. Agent designation, FDA registration, and compliance guidance. Contact us for support navigating the FDA regulatory landscape.